Galectin Therapeutics Inc. (GALT): Net earnings per share for the last 12 months

Symbol and logo of brand Galectin Therapeutics, Inc. (GALT)

Galectin Therapeutics (GALT) relies on a closed cirrhosis therapy system, creating high barriers to entry for competitors. The annual net income per share trend confirms this stability, with -0.43 representing the current metric value. A focus on advanced stages of fibrosis ensures long-term patent monetization, although late-stage trials temporarily increase capital expenditures due to the absence of revenue.

GALT (Galectin Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/15/2026

Analytical breakdowns for Galectin Therapeutics

- stock price and consensus target price:
Stock Price Galectin Therapeutics, Inc.|GALT - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Galectin|GALT - Total Company Value
- balance sheet net asset value indicators:
Book Value per Share Galectin Therapeutics|GALT - Total Stockholders' Equity|Market Value to Book Value Ratio galectintherapeutics.com|GALT - Aggregate Asset Value
- company total debt and liquidity indicators:
Total Debt to Capital Galectin Therapeutics|GALT - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Galectin Therapeutics|GALT - Company Aggregate Debts|Debt to Book Capitalization Ratio Galectin|GALT - Company Long-Term Debt|Company Short-Term Debts Galectin Therapeutics|Quick Ratio galectintherapeutics.com
- net income and valuation multiples indicators:
GALT - Net Income|Future Profit Galectin Therapeutics|GALT - Market Price to Net Income Ratio|Forward P/E Multiple Galectin Therapeutics, Inc.|GALT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galectin Therapeutics|GALT - Operating profit before amortization|Net earnings per share for the last 12 months Galectin Therapeutics|GALT - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months galectintherapeutics.com|GALT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Galectin Therapeutics
- revenue and sales proceeds data:
GALT - Company Sales Revenue|Projected Sales Volume Galectin|GALT - Price to Sales|Price-to-Projected Revenue Ratio Galectin Therapeutics Inc.|GALT - Revenue Dynamics YoY (Last Twelve Months)
Analysis of all company metrics:GALT - Galectin Therapeutics, Inc.
Manufactured products of Galectin Therapeutics, Inc.

Galectin Therapeutics pharmaceutical operations are exposed to risks of supply chain disruptions from Asia and patent disputes affecting development costs. By analyzing the TTM net income per share, an investor assesses the real equity value of the business over a year excluding dilution, which allows for the distinction between sustainable capitalization growth and short-term market volatility.

Competitor analysis for Galectin Therapeutics

Arrowhead Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Mirum Pharma MIRM|DVAX (Dynavax Technologies) - Net earnings per share for the last 12 months|ABUS (Arbutus) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Inventiva S.A.|Net earnings per one share for the last twelve months gyretx.com GYRE|Earnings per share for the last twelve months Assembly Biosciences, Inc. (ASMB)|GNFT (GENFIT) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) DRRX (durect.com)|Net earnings per share (EPS TTM) Aligos Therapeutics ALGS|BioVie Inc - Net earnings per share (EPS TTM)|GLMD - Net earnings per share (EPS TTM)|NDRA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months HEPA (Hepion Pharmaceuticals Inc.)